Abingdon Health PLC

05 April 2022

Abingdon Health plc

("Abingdon" or "the Company")

Completion of Technical Transfer to full-scale manufacture and initial orders for Vatic KnowNow(TM) test

Tests manufactured by Abingdon now authorised for sale

York, U.K. 5 April 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, announces it has successfully completed the technical transfer of the Vatic KnowNow test (Spike Test in USA) on behalf of its customer, leading diagnostics technology innovator Vatic Health Limited ("Vatic"), on schedule. This follows the conclusion of the scale-up and manufacture of three independent production-scale batches and Vatic has now approved the sale of tests manufactured by Abingdon. Abingdon has received initial purchase orders from Vatic for commercial sale, and manufacturing for these orders will now commence.

The Vatic KnowNow test is an easy-to-use saliva COVID-19 antigen test, which is the only test that identifies the virus by mimicking the surface of a human cell. This means the test only identifies "live" or "active" copies of the virus which are capable of cell entry and thereby infecting a human cell. Other tests, such as PCR and lateral flow antigen tests, can pick up harmless viral fragments with the potential for users to test positive once they are no longer infectious. Furthermore, the unique detection mechanism of the KnowNow test has been purposefully designed to be more robust to mutation than traditional antigen tests, making it more future-proofed for ongoing COVID-19 testing. Vatic have previously announced that this test detects variants of the SARS-CoV-2 virus including the Omicron variant.

The test is CE marked for professional use and has been submitted by Vatic to the US FDA for Emergency Use Approval (EUA).

Alex Sheppard, CEO of Vatic Health Limited, commented:

"We are excited to have concluded the transfer of our product to manufacture with Abingdon and to commence sales of our product. Our proprietary technology allows ease of use via a saliva specimen and only detects active virus -enabling individuals to know their infectivity status."

Dr Mona K. Omir, CTO of Vatic Health Limited, commented:

"Completing the Technical Transfer of the KnowNow test is a huge milestone in the Vatic Health journey and our ongoing collaboration with Abingdon Health. To bring such novel assay technology into routine manufacturing could be a true step change in diagnostics and we are excited for what this could mean for COVID-19 testing around the world."

Chris Yates, CEO of Abingdon Health plc, commented:

"We are delighted to have concluded this technical transfer and to begin manufacture of the product for Vatic at our Yorkshire facilities. This is an important addition to the COVID-19 testing toolbox and we look forward to continuing to work with Vatic as we manufacture the product to fulfil their requirements."


 Abingdon Health plc                                   www.abingdonhealth.com/investors/ 
 Chris Yates, Chief Executive Officer                                    Via Walbrook PR 
 Melanie Ross, Chief Financial Officer 
 Dr Chris Hand, Non-Executive Chairman 
 Singer Capital Markets (Sole Broker and                        Tel: +44 (0)20 7496 3000 
  Nominated Adviser) 
 Shaun Dobson, Peter Steel, Alex Bond (Corporate 
 Tom Salvesen (Corporate Broking) 
 Walbrook PR Limited                 Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com 
 Paul McManus / Phillip                       Mob: +44 (0)7980 541 893 / +44 (0)7867 984 
  Marriage                                                                           082 
 Alice Woodings                                                 Mob: +44 (0)7407 804 654 

About Abingdon Health plc

Abingdon Health is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.

The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx(R) , a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader.

Founded in 2008, Abingdon Health is headquartered in York, England.

For more information visit: www.abingdonhealth.com

About Vatic Health

Vatic Health is an Innovate UK and VC backed start-up, supported by the University of Oxford and the Oxford Foundry. They are a team of scientists, engineers and designers solving the world's most critical healthcare problems with a focus on the inequality of access to health data.

Vatic's vision is a world in which everyone has access to proactive diagnostic tools in the community and at home. This means the rapid tools to help people know about acute illness before it happens, and a way to assess this data and turn it into personalised, actionable insights that provide real benefits to real people.

They take a unique approach to lateral flow immunoassays, taking inspiration from nature to create novel rapid tests with dramatically increased sensitivity of detection, unlike traditional approaches. The first deployment of this proprietary technology is in its COVID-19 test (KnowNow(TM), EU and Spike Test, USA).

Founded in 2019, Vatic Health is headquartered in London, England.

For more information visit: www.vatic.health

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

April 05, 2022 02:01 ET (06:01 GMT)

Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Jun 2022 to Jul 2022 Click Here for more Abingdon Health Charts.
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Jul 2021 to Jul 2022 Click Here for more Abingdon Health Charts.